ESSEXBIO-TECH：INTERIMREPORT2021.pdf

1、2021InterimReport2021中期報告中期報告INTERIM REPORT 2021 CONTENTS2Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income3Condensed Consolidated Statement of Financial Position4Condensed Consolidated Statement of Changes in Equity5Condensed Consolidated Statement of Cash Flows7Note

2、s to the Interim Condensed Consolidated Financial Statements24Management Discussion and Analysis38Additional Information42Corporate Information2ESSEX BIO-TECHNOLOGY LIMITEDINTERIM REPORT 2021The board(the“Board”)of directors(the“Directors”)of Essex Bio-Technology Limited(the“Company”)presents the un

3、audited interim condensed consolidated financial statements of the Company and its subsidiaries(collectively,the“Group”)for the six months ended 30 June 2021 together with the comparative figures for the corresponding period in 2020 and the relevant explanatory notes as set out below.CONDENSED CONSO

4、LIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOMEFor the six months ended 30 June20212020(Unaudited)(Unaudited)NotesHK$000HK$000Turnover4&5737,374323,835Cost of sales(114,680)(69,125)Gross profit622,694254,710Other revenue,and other gains and losses612,08315,747Distribution and sell

5、ing expenses(377,280)(163,537)Administrative expenses(69,061)(45,749)Finance costs7(5,362)(3,381)Profit before income tax8183,07457,790Income tax9(20,888)(8,602)Profit for the period162,18649,188Other comprehensive incomeItems that may be reclassified subsequently to profit or loss:Exchange differen

6、ces on translation of financial statements of foreign operations18,586(27,261)Items that will not be reclassified subsequently to profit or loss:Changes in fair value of equity instruments at fair value through other comprehensive income(560)(19,101)Other comprehensive income for the period18,026(46